Specific protection against breast cancers by cyclin D1 ablation
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Breast cancer is the most common malignancy among women. Most of these cancers overexpress cyclin D1, a component of the core cell-cycle machinery. We previously generated mice lacking cyclin D1 using gene targeting. Here we report that these cyclin D1-deficient mice are resistant to breast cancers induced by the neu and ras oncogenes. However, animals lacking cyclin D1 remain fully sensitive to other oncogenic pathways of the mammary epithelium, such as those driven by c-myc or Wnt-1. Our analyses revealed that, in mammary epithelial cells, the Neu-Ras pathway is connected to the cell-cycle machinery by cyclin D1, explaining the absolute dependency on cyclin D1 for malignant transformation in this tissue. Our results suggest that an anti-cyclin D1 therapy might be highly specific in treating human breast cancers with activated Neu-Ras pathways.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“genetically engineered mouse models clearly revealed the importance of cyclin D1-CDK4 activity for the initiation and maintenance of HER2-driven breast cancers (98-100)”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [98]
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
β-Catenin regulates expression of cyclin D1 in colon carcinoma cells
Tetsu, O., & McCormick, F. (1999) · Nature · doi:10.1038/18884 · Cited by 3,601
Cyclin D1 Expression Is Regulated Positively by the p42/p44 and Negatively by the p38/HOG Pathway
Lavoie, J. N., L'Allemain, G., Brunet, A., Müller, R., & Pouysségur, J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.34.20608 · Cited by 1,211 · cited 1×
“Discussion The ras oncogene, acting through the mitogen-activated protein kinase pathway, is known to induce cyclin D1 by acting on cyclin D1 promote”
BackgroundMuller, W. J., Sinn, E., Pattengale, P. K., Wallace, R., & Leder, P. (1988) · Cell · doi:10.1016/0092-8674(88)90184-5 · Cited by 1,165
Cyclin D1 provides a link between development and oncogenesis in the retina and breast
Sicinski, P., Donaher, J. L., Parker, S. B., Li, T., Fazeli, A., Gardner, H., Haslam, S. Z., Bronson, R. T., Elledge, S. J., & Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90034-9 · Cited by 1,021
Bargmann, C. I., Hung, M.-C., & Weinberg, R. A. (1986) · Cell · doi:10.1016/0092-8674(86)90779-8 · Cited by 1,006
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
Wang, T. C., Cardiff, R. D., Zukerberg, L., Lees, E., Arnold, A., & Schmidt, E. V. (1994) · Nature · doi:10.1038/369669a0 · Cited by 965
Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes
Stewart, T. A., Pattengale, P. K., & Leder, P. (1984) · Cell · doi:10.1016/0092-8674(84)90257-5 · Cited by 899
Transforming p21 Mutants and c-Ets-2 Activate the Cyclin D1 Promoter through Distinguishable Regions
Albanese, C., Johnson, J., Watanabe, G., Eklund, N., Vu, D., Arnold, A., & Pestell, R. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.40.23589 · Cited by 803
Sinn, E., Muller, W., Pattengale, P., Tepler, I., Wallace, R., & Leder, P. (1987) · Cell · doi:10.1016/0092-8674(87)90449-1 · Cited by 792
Cited by
Items 201–300 of 937
Panupinthu, N., Lee, H. Y., & Mills, G. B. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605588 · Cited by 132
“In addition, the presence of cyclin D1 was essential for Ras-induced transformation of mammary epithelial cells (Yu et al, 2001).”
BackgroundDACH1 Is a Cell Fate Determination Factor That Inhibits Cyclin D1 and Breast Tumor Growth
Wu, K., Li, A., Rao, M., Liu, M., Dailey, V. K., Yang, Y., Vizio, D. D., Wang, C., Lisanti, M. P., Sauter, G., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00268-06 · Cited by 139
“Cyclin D1 / cells derived from cyclin D1 / mice (64), p21 / fibroblast cells (provided by L.”
BackgroundWeng, J.-R., Chen, C.-Y., Pinzone, J. J., Ringel, M. D., & Chen, C. S. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01182 · Cited by 151
“First, cyclin D1 ablation provides specific protection against breast carcinogenesis (Yu et al. 2001).”
BackgroundJeselsohn, R., Brown, N. E., Arendt, L., Klebba, I., Hu, M. G., Kuperwasser, C., & Hinds, P. W. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.024 · Cited by 127
“Our data can also explain the described differential susceptibility of cyclin D1 knockout mice to different mammary oncogenes (Yu et al., 2001).”
BackgroundNuclear receptors in cell life and death
Altucci, L., & Gronemeyer, H. (2001) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(01)00502-1 · Cited by 144
Modulation of signal transduction by tea catechins and related phytochemicals
Shimizu, M., & Weinstein, I. B. (2005) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2005.04.010 · Cited by 133
Witkiewicz, A. K., & Knudsen, E. S. (2014) · Breast Cancer Research · doi:10.1186/bcr3652 · Cited by 125
“Sicinski’s laboratory investigated the relationship of cyclin D1 genetic loss with the development of mammary tumors in mice whose tumors were driven by multiple different genetic stresses [76].”
BackgroundTGFBI Deficiency Predisposes Mice to Spontaneous Tumor Development
Zhang, Y., Wen, G., Shao, G., Wang, C., Lin, C., Fang, H., Balajee, A. S., Bhagat, G., Hei, T. K., & Zhao, Y. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1648 · Cited by 136
SUMO1 modification stabilizes CDK6 protein and drives the cell cycle and glioblastoma progression
Bellail, A. C., Olson, J. J., & Hao, C. (2014) · Nature Communications · doi:10.1038/ncomms5234 · Cited by 122
“Chen (University of Texas Southwestern Medical center, TX) for kindly providing the plasmid YFP-SUMO1∆C4 (1-97), YFP-SUMO3∆C11, pcDNA3 6xHis/SUMO1, pCMV-myc-UBC9, pEF-IRES-P-HA-UbK48, pEF-IRES-P-HA-Ub-K0, pEF-IRES-P-HA-Ub-WT and pEF-IRES-P-HA-R48.”
BackgroundFoxM1 is a downstream target and marker of HER2 overexpression in breast cancer
Lam (2009) · International Journal of Oncology · doi:10.3892/ijo_00000313 · Cited by 123
“Wildtype and MMTV-c-neu mice described previously (30) were maintained at Dana-Faber Cancer Institute facilities, Harvard Medical School, Boston, MA, USA.”
Huang, J., Shiau, C., Yang, Y.-T. C., Kulp, S. K., Chen, K., Brueggemeier, R. W., Shapiro, C. L., & Chen, C. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.007732 · Cited by 142
“Together, these findings suggest that an anticyclin D1 therapy might be highly specific for treating human breast cancer (Yu et al., 2001).”
BackgroundCai, J., Wu, J., Zhang, H., Fang, L., Huang, Y., Yang, Y., Zhu, X., Li, R., & Li, M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2651 · Cited by 125
“Ablation of cyclin D1 specifically protects mammary tissues from malignancy (32).”
Chandarlapaty, S., Scaltriti, M., Angelini, P., Ye, Q., Guzman, M., Hudis, C. A., Norton, L., Solit, D. B., Arribas, J., Baselga, J., et al. (2010) · Oncogene · doi:10.1038/onc.2009.337 · Cited by 123
“…pathways, especially HER2/HER3-dimer dependent activation of PI3K/AKT signaling, with attendant increases in D-cyclin expression, deregulation of proliferation and desensitization of the tumor to apoptotic stimuli (Basso et al., 2002; Holbro et al., 2003; Yakes et al., 2002; Yu et al., 2001).”
BackgroundCyclin D1 Induction of Cellular Migration Requires p27KIP1
Li, Z., Jiao, X., Wang, C., Ju, X., Lu, Y., Yuan, L., Lisanti, M. P., Katiyar, S., & Pestell, R. G. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1596 · Cited by 124
“Molecular genetic analysis in transgenic animals has shown an essential role for cyclin D1 in the onset and progression of mammary tumorigenesis induced by Ras or ErbB2 (3) or gastrointestinal tumorigenesis induced by mutation of the Apc gene (4).”
BackgroundKiaris, H., Politi, K. A., Grimm, L. M., Szabolcs, M. J., Fisher, P. E., Efstratiadis, A., & Artavanis‐Tsakonas, S. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63333-0 · Cited by 135
“Similarly, c-Myc induced oncogenesis in mouse mammary glands is not inhibited in a genetic background lacking cyclin D1.”
BackgroundInfluentialProlyl isomerase Pin1 as a molecular target for cancer diagnostics and therapeutics
Lu, K. P. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00218-6 · Cited by 133
Role of Cannabinoid Receptor CB2 in HER2 Pro-oncogenic Signaling in Breast Cancer
Pérez-Gómez, E., Andradas, C., Blasco-Benito, S., Caffarel, M. M., García-Taboada, E., Villa‐Morales, M., Moreno, E., Hamann, S., Martín-Villar, E., Flores, J. M., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv077 · Cited by 135
Witkiewicz, A. K., Cox, D., & Knudsen, E. S. (2014) · Genes & Cancer · doi:10.18632/genesandcancer.24 · Cited by 121
“Deregulated CDK4/6 activity can induce mammary tumor development in mice, and conversely disruption of the activity will limit tumor development (32-34).”
BackgroundChen, C., Chang, Y., Liu, C., Chang, K., & Guo, I.-C. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9139-y · Cited by 134
“However, mice deficient in cyclin D1 remained full sensitive to c-Myc oncogenic pathway to develop breast cancer [30], suggesting that alternative cell-cycle regulators can mediate c-Myc-induced tumorigenesis.”
BackgroundThe Involvement of Ubiquitination Machinery in Cell Cycle Regulation and Cancer Progression
Zou, T., & Lin, Z. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115754 · Cited by 133
From milk to malignancy: the role of mammary stem cells in development, pregnancy and breast cancer
Tiede, B., & Kang, Y. (2011) · Cell Research · doi:10.1038/cr.2011.11 · Cited by 145
Development of Pure Prolactin Receptor Antagonists
Bernichtein, S., Kayser, C., Dillner, K., Moulin, S., Kopchick, J. J., MARTIAL, J. A., Norstedt, G., Isaksson, O. G. P., Kelly, P. A., & Goffin, V. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305687200 · Cited by 120
Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation
Davis, B. B., Thompson, D. A., Howard, L. L., Morisseau, C. H. P., Hammock, B. D., & Weiss, R. H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261710799 · Cited by 120
Rampalli, S., Pavithra, L., Bhatt, A., Kundu, T. K., & Chattopadhyay, S. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.19.8415-8429.2005 · Cited by 114
“Elevation of cyclin D1 mRNA in 50 to 70% of breast cancers, while failing to develop normal mammary glands in transgenic mice lacking both cyclin D1 alleles, associates its role in cancer as well as normal breast development (35, 47).”
BackgroundMouse Mammary Tumor Virus c-rel Transgenic Mice Develop Mammary Tumors
Romieu-Mourez, R., Kim, D. W., Shin, S. M., Demicco, E. G., Landesman-Bollag, E., Seldin, D. C., Cardiff, R. D., & Sonenshein, G. E. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.16.5738-5754.2003 · Cited by 119
“Female mice deficient for cyclin D1 are on A pril 27, 2019 by guest http://m cb.asm .org/ D ow nloaded from totally resistant to breast cancers induced by Neu and Ras, but not to those induced by Myc and Wnt-1 (68).”
BackgroundInfluentialHsa-miR-326 targets CCND1 and inhibits non-small cell lung cancer development
Sun, C., Huang, C., Li, S., Yang, C., Xi, Y., Wang, L., Zhang, F., Fu, Y., & Li, D. (2016) · Oncotarget · doi:10.18632/oncotarget.7071 · Cited by 124
“…negatively expressed related to miR-326 cyclin D1 is important oncogene that shown strong power of oncogenicity, by promotion of cell growth, migration, invasion and epithelial mesenchymal transition (EMT), as well as inhibition of cell apoptosis in many tumors including lung cancer [35, 41, 42].”
Cellular senescence: a double-edged sword in cancer therapy
Xiao, S., Qin, D., Hou, X., Tian, L., Yu, Y., Zhang, R., Lyu, H., Guo, D. S., Chen, X., Zhou, C., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1189015 · Cited by 144
“Therefore, CDK4/6 as an important antitumor target, was developed as a chemotherapeutic drug for cancer therapy (66, 67).”
BackgroundCyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS
Taylor‐Harding, B., Aspuria, P.-J. P., Agadjanian, H., Cheon, D., Mizuno, T., Greenberg, D. N., Allen, J. R., Spurka, L., Funari, V. A., Spiteri, E., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2673 · Cited by 124
Suizu, F., Ryo, A., Wulf, G., Lim, J., & Lu, K. P. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.4.1463-1479.2006 · Cited by 118
“Since cyclin D1 plays an essential role in breast cancer development (15, 37, 72, 77, 86) and can increase centrosome duplication in vitro (55), it is possible that Pin1 might regulate centrosome duplication and breast cancer through cyclin D1 and its upstream regulators.”
BackgroundLiao, D. J., Thakur, A. B., Wu, J., Biliran, H., & Sarkar, F. H. (2007) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v13.i2.10 · Cited by 125
Muraoka, R. S., Lenferink, A. E. G., Law, B., Hamilton, E., Brantley, D. M., Roebuck, L. R., & Arteaga, C. L. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.7.2204-2219.2002 · Cited by 118
“In contrast, cyclin D1 in the mammary gland is required for Neuor Ras-induced breast cancers (65), and its overexpression in the mammary epithelia of transgenic mice results in ductal hyperplasia (59).”
BackgroundInfluentialMazurek, A., Luo, W., Krasnitz, A., Hicks, J. B., Powers, S., & Stillman, B. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0116 · Cited by 127
ChIP sequencing of cyclin D1 reveals a transcriptional role in chromosomal instability in mice
Casimiro, M. C., Crosariol, M., Loro, E., Ertel, A., Yu, Z., Dampier, W., Saria, E. A., Papanikolaou, A., Stanek, T. J., Li, Z., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60256 · Cited by 115
“Cyclin D1 is required for oncogene-dependent growth, as genetic ablation of murine Ccnd1 impaired terminal alveolar breast bud development (20) and resulted in resistance to Ras-or ErbB2-induced mammary tumorigenesis and to APC-induced gastrointestinal tumorigenesis (21, 22).”
Mechanisms of tumour invasion and metastasis: emerging targets for therapy
Thompson, E. W., & Price, J. T. (2002) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.6.2.217 · Cited by 127
“Moreover, the action of β-catenin and its signalling have been shown in a number of cancer types [85] and transcriptional targets, such as cyclin D1 (which has been shown to negatively correlate with E-cadherin expression), have been implicated in tumour metastasis [86-88].”
BackgroundCiruelos, E., Villagrasa, P., Pascual, T., Oliveira, M., Pernas, S., Paré, L., Escrivá-de-Romaní, S., Manso, L., Adamo, B., de Dueñas, E. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0844 · Cited by 119
“In addition, Cyclin D1 expression mediates resistance to HER2-targeted therapies (24, 25) and this mechanism is overcome through CDK4/6i (26, 27).”
BackgroundBundy, L. M., & Sealy, L. J. (2003) · Oncogene · doi:10.1038/sj.onc.1206216 · Cited by 122
“In addition, the progeny of cyclin D1 null animals crossbred with other mouse models of mammary tumorigenesis fail to develop mammary tumors (Yu et al., 2001).”
BackgroundVanderlaag, K. E., Hudak, S., Bald, L., Fayadat-Dilman, L., Sathe, M., Grein, J., & Janatpour, M. J. (2010) · Breast Cancer Research · doi:10.1186/bcr2586 · Cited by 93
“Gergely P Jr, Grossman C, Niland B, Puskas F, Neupane H, Allam F, Banki K, Phillips PE, Perl A: Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus.”
BackgroundTargeting the Checkpoint to Kill Cancer Cells
Benada, J., & Macůrek, L. (2015) · Biomolecules · doi:10.3390/biom5031912 · Cited by 124
“This has been first demonstrated for cyclin D1 and CDK4/6 that are required for development of RAS- and HER2-driven mammary tumors and KRAS-induced lung tumors [152–154].”
BackgroundPei, X.-H., Bai, F., Smith, M. D., Usary, J., Fan, C., Pai, S.-Y., Ho, I.-C., Perou, C. M., & Xiong, Y. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.004 · Cited by 110
“Second, deletion in mice of cyclin D1 or CDK4, the target of p18, conversely retards mammary gland development and prevents MMTV-oncogene induced mammary cancer (Fantl et al., 1995; Sicinski et al., 1995; Yu et al., 2001; Yu et al., 2006).”
Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models
Sutherland, R. L., & Musgrove, E. A. (2001) · Breast Cancer Research · doi:10.1186/bcr411 · Cited by 118
“Wnt-1 induced precocious mammary gland development in cyclin D1 null mice, indicating that it could replace cyclin D1 function in both development and tumourigenesis [1].”
BackgroundInfluentialAlao, J. P., Lam, E. W.-F., Ali, S., Buluwela, L., Bordogna, W., Lockey, P., Varshochi, R., Stavropoulou, A. V., Coombes, R. C., & Vigushin, D. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1023 · Cited by 112
“Transgenic mice that overexpress cyclin D1 in mammary tissue develop breast cancers (12) and cyclin D1-deficient mice are resistant to breast cancers induced by neu and ras oncogenes (13).”
BackgroundThe tumour suppressor C/EBPδ inhibits FBXW7 expression and promotes mammary tumour metastasis
Balamurugan, K., Wang, J., Tsai, H.-H., Sharan, S., Anver, M. R., Leighty, R. M., & Sterneck, E. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.280 · Cited by 119
“Cyclin D1 ablation was shown to protect mice from Neu-mediated mammary tumourigenesis (Yu et al, 2001).”
BackgroundMethodInfluentialGenetic and epigenetic alterations as hallmarks of the intricate road to cancer
Macaluso, M., Paggi, M. G., & Giordano, A. (2003) · Oncogene · doi:10.1038/sj.onc.1206955 · Cited by 127
“…addition, it has been shown that there is an absolute requirement for the cyclin D1 overexpression in breast malignancy trasformation that cannot be complemented by the other related cyclins D2 and D3, suggesting a putative anti-cyclin D1 therapy highly specific for breast cancer (Yu et al., 2001).”
BackgroundGenetic ablation of Cyclin D1 abrogates genesis of rhabdoid tumors resulting from Ini1 loss
Tsikitis, M., Zhang, Z., Edelmann, W., Zagzag, D., & Kalpana, G. V. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505300102 · Cited by 125
Wang, C., Lisanti, M. P., & Liao, D. J. (2011) · Cell Cycle · doi:10.4161/cc.10.1.14449 · Cited by 109
K63-Linked Ubiquitination in Kinase Activation and Cancer
Wang, G., Gao, Y., Li, L., Jin, G., Cai, Z., Chao, J. I., & Lin, H.-K. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00005 · Cited by 124
“In addition, inactivation of Cyclin D1 can abolish breast cancer development driven by oncogenic Ras or Neu (Lee et al., 2000; Yu et al., 2001).”
BackgroundPalbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer
Rocca, A., Farolfi, A., Bravaccini, S., Schirone, A., & Amadori, D. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.870555 · Cited by 117
“This has been attributed to the fact that the neu-ras pathway is closely connected to the cell-cycle machinery by cyclin D1, and suggests potential activity of anti-cyclin D1-CDK4/6 agents in these tumors [29].”
BackgroundCanonical Wnt pathway gene expression and their clinical correlation in oral squamous cell carcinoma
Marimuthu, M., Andiappan, M., U, A. W. P., Muthusekhar, M. R., Balakrishnan, A., & Shanmugam, S. (2018) · Indian Journal of Dental Research · doi:10.4103/ijdr.ijdr_375_17 · Cited by 125
“Studies have shown that Wnt does not require cyclin D1 because tumors can develop in cyclin D1 knockout mice.[21] Similarly, in vitro studies have shown that c‐MYC is an inhibitor of cyclin D1 expression and c‐MYC‐dependent pathways do not need Cyclin D1.”
BackgroundMolecular targets of [6]‐gingerol: Its potential roles in cancer chemoprevention
Oyagbemi, A. A., Saba, A. B., & Azeez, O. I. (2010) · BioFactors · doi:10.1002/biof.78 · Cited by 115
“Cyclin D1 is probably one of the most important NF-jB target genes in normal mammary gland development and mammary carcinogenesis [87] and it has been shown that cyclin D1 expression requires a functioning NF-jB activation pathway during mammary gland development [88].”
BackgroundRazandi, M., Pedram, A., Rosen, E. M., & Levin, E. R. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.13.5900-5913.2004 · Cited by 108
“This is considered to be important for the proliferation of breast cancer (51).”
BackgroundActivation of cyclin D1 expression by the ERK5 cascade
Mulloy, R., Salinas, S., Philips, A., & Hipskind, R. A. (2003) · Oncogene · doi:10.1038/sj.onc.1206839 · Cited by 132
“…suggests, mice engineered to overexpress cyclin D1 die from breast cancer (Wang et al., 1994), while mammary tissue from mice lacking cyclin D1 is insensitive to the transforming effects of activated ras and neu but is still sensitive to other oncogenes, such as myc and wnt-1 (Yu et al., 2001).”
BackgroundMolecular crosstalk between cancer and neurodegenerative diseases
Seo, J., & Park, M. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03428-3 · Cited by 114
Venkatachalam, K., Vinayagam, R., Anand, M. A. V., Isa, N. M., & Ponnaiyan, R. (2020) · Toxicology Research · doi:10.1093/toxres/tfaa004 · Cited by 122
“Other substances such as curcumin, trans-resveratrol, or parthenolide are natural compounds that have been demonstrated to inhibit IKK activity [143].”
BackgroundPin1 inhibitors: Pitfalls, progress and cellular pharmacology
Moore, J. D., & Potter, A. J. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.05.088 · Cited by 113
Cyclin-Dependent Kinase 4 Expression Is Essential for Neu-Induced Breast Tumorigenesis
Reddy, H. K. D. L., Mettus, R. V., Rane, S. G., Graña, X., Litvin, J., & Reddy, E. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2639 · Cited by 104
“induced by wnt-1 and c-myc , but not neu or ras (16).”
BackgroundInfluentialHeathcote, D. A., Patel, H., Kroll, S. H. B., Hazel, P., Periyasamy, M., Alikian, M., Kanneganti, S. K., Jogalekar, A. S., Scheiper, B., Barbazanges, M., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100732t · Cited by 113
Role of Glycogen Synthase Kinase 3β in Rapamycin-Mediated Cell Cycle Regulation and Chemosensitivity
Dong, J., Peng, J., Zhang, H., Mondesire, W. H., Jian, W., Mills, G. B., Hung, M., & Meric‐Bernstam, F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2501 · Cited by 111
García-Silva, S., & Aranda, A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.17.7514-7523.2004 · Cited by 112
“Thus, analysis in cyclin D1 knockout mice reveals that this protein is required for rasdependent malignant transformation of the mammary glands (50).”
BackgroundYang, W.-L., Zhang, X., & Lin, H.-K. (2010) · Oncogene · doi:10.1038/onc.2010.190 · Cited by 115
“Cyclin D1 is also upregulated in human cancers, and its inactivation abolishes breast cancer development driven by oncogenic Ras or Neu (Lee et al., 2000; Yu et al., 2001).”
Foster, J. S., Fernando, R. I., Ishida, N., Nakayama, K. I., & Wimalasena, J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302830200 · Cited by 103
Dai, M., Al-Odaini, A. A., Fils-Aimé, N., Villatoro, M. A., Guo, J., Arakelian, A., Rabbani, S. A., Ali, S., & Lebrun, J. J. (2013) · Breast Cancer Research · doi:10.1186/bcr3441 · Cited by 100
“Furthermore, cyclin D1 is required for many oncogenes, such as HER2 or Ras, to induce mammary tumor growth in mice [57-59].”
BackgroundResultSun, C., Li, S., & Li, D. (2016) · Oncotarget · doi:10.18632/oncotarget.8482 · Cited by 104
Lack of Cyclin-Dependent Kinase 4 Inhibits c-myc Tumorigenic Activities in Epithelial Tissues
Miliani de Marval, P. L., Macias, E., Rounbehler, R., Sicinski, P., Kiyokawa, H., Johnson, D. G., Conti, C. J., & Rodriguez-Puebla, M. L. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.17.7538-7547.2004 · Cited by 101
“In contrast, Ras can cause oncogenic transformation of fibroblasts in the absence of cyclin D1 (74), while cyclin D1-deficient skin keratinocytes show reduced susceptibility to chemical tumorigenesis (57, 59).”
BackgroundDifferential gene regulation by the SRC family of coactivators
Zhang, H., Yi, X., Sun, X., Yin, N., Shi, B., Wu, H., Wang, D., Wu, G., & Shang, Y. (2004) · Genes & Development · doi:10.1101/gad.1194704 · Cited by 107
“…carcinomas (Guerin et al. 1988; Bieche et al. 1999; Chrzan et al. 2001; Naidu et al. 2002), and cMyc has been implicated in cell growth, proliferation, apoptosis, and malignant transformation, including breast cancer carcinogenesis (D’Cruz et al. 2001; Nasi et al. 2001; Yu et al. 2001).”
BackgroundOncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells
Sabnis, A. J., Cheung, L. S., Dail, M., Kang, H. C., Santaguida, M. A., Hermiston, M. L., Passegue, E. A., Shannon, K., & Braun, B. S. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000059 · Cited by 106
“If increased cyclin D1 levels conversely result in excessive proliferation of HSC, then MPD in Kras mice may be mediated in part by cyclin D1, similar to the requirement for cyclin D1 in a model of Ras-mediated breast cancer [42].”
BackgroundMiettinen, T. P., Peltier, J., Härtlova, A., Gierliński, M., Jansen, V. M., Trost, M., & Björklund, M. (2018) · The EMBO Journal · doi:10.15252/embj.201798359 · Cited by 101
“…D inhibition may be additionally beneficial for the treatment of human epidermal growth factor receptor 2 (HER2) and RAS-driven breast cancers (Yu et al , 2001; Goel et al , 2016) and potentially many other cancers because cyclin D1 displays most frequent somatic copy number aberrations of…”
Targeting Receptor Tyrosine Kinases for Chemoprevention by Green Tea Catechin, EGCG
Shimizu, M., Shirakami, Y., & Moriwaki, H. (2008) · International Journal of Molecular Sciences · doi:10.3390/ijms9061034 · Cited by 107
“It is interesting to note that the cyclin D1 expression is required for breast carcinogenesis following mammary-specific expression of the HER2 or H-ras oncogenes [58].”
BackgroundHaploinsufficiency of p18INK4c Sensitizes Mice to Carcinogen-Induced Tumorigenesis
Bai, F., Pei, X.-H., Godfrey, V. L., & Xiong, Y. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.4.1269-1277.2003 · Cited by 100
Niu, Y., Xu, J., & Sun, T. (2019) · Journal of Cancer · doi:10.7150/jca.32628 · Cited by 110
“Numerous preclinical studies have shown that cyclin D1-CDK4/6 is a necessary factor in sustaining the tumorigenic potential of breast cancer cells [6-8].”
BackgroundUmekita, Y., Ohi, Y., Sagara, Y., & Yoshida, H. (2002) · International Journal of Cancer · doi:10.1002/ijc.10151 · Cited by 98
Fereshteh, M. P., Tilli, M. T., Kim, S. E., Xu, J., O'Malley, B. W., Wellstein, A., Furth, P. A., & Riegel, A. T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6702 · Cited by 97
“cell cycle progression, mammary gland development, and tumor progression (24, 25).”
BackgroundHickman, J. A. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(01)00266-0 · Cited by 98
Estrogen Carcinogenesis in Breast Cancer
Germain, D. (2011) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2011.05.009 · Cited by 108
Is Cyclin D1-CDK4 kinase a bona fide cancer target?
Malumbres, M., & Barbacid, M. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.026 · Cited by 107
Larionov, A. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00089 · Cited by 102
“Surprisingly, despite the central role of Cyclin D1 in cell cycle regulation, mice lacking Cyclin D1 are viable and resistant to HER2(neu)-induced breast cancers (but not to breast cancers induced by MYC) (138).”
Background4-(Pyrazol-4-yl)-pyrimidines as Selective Inhibitors of Cyclin-Dependent Kinase 4/6
Cho, Y. S., Borland, M., Brain, C., Chen, C. H.-T., Cheng, H., Chopra, R., Chung, K., Groarke, J., He, G., Hou, Y., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100571n · Cited by 91
Way, T., Kao, M., & Lin, J. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.11.061 · Cited by 108
“cient mice were completely resistant to erbB2-mediated mammary tumorigenesis [9].”
BackgroundCyclin D1 Antagonizes BRCA1 Repression of Estrogen Receptor α Activity
Wang, C., Fan, S., Li, Z., Fu, M., Rao, M., Ma, Y., Lisanti, M. P., Albanese, C., Katzenellenbogen, B. S., Kushner, P. J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0486 · Cited by 93
“Evidence for a biologically relevant role for cyclin D1 in breast tumorigenesis includes findings that mammary gland–targeted cyclin D1 overexpression induced mammary tumors in transgenic mice (20), cyclin D1 antisense blocked ErbB2-induced mammary tumor growth in vivo (21), and mice deleted of the cyclin D1 gene were…”
BackgroundWitkiewicz, A. K., Cox, D., & Knudsen, E. S. (2021) · Genes & Cancer · doi:10.18632/genesandcancer.211 · Cited by 91
Mitra, D., Das, P. M., Huynh, F. C., & Jones, F. E. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.304865 · Cited by 98
Opposing Roles of Mitogenic and Stress Signaling Pathways in the Induction of Cancer Dormancy
Ranganathan, A. C., Adam, A. P., & Aguirre‐Ghiso, J. A. (2006) · Cell Cycle · doi:10.4161/cc.5.16.3109 · Cited by 103
Loss of cyclin D1 impairs cerebellar development and suppresses medulloblastoma formation
Pogoriler, J. E., Millen, K. J., Utset, M. F., & Du, W. (2006) · Development · doi:10.1242/dev.02556 · Cited by 102
“In mouse breast tumor models, the inhibition of tumorigenesis in Ccnd1–/– tissue has been linked to the ability of an oncogenic signaling pathway to upregulate cyclin D1 specifically (Yu et al., 2001).”
BackgroundMethodFassl, A., Brain, C. T., Abu-Remaileh, M., Stukan, I., Butter, D., Stępień, P., Feit, A. S., Bergholz, J. S., Michowski, W., Otto, T., et al. (2020) · Science Advances · doi:10.1126/sciadv.abb2210 · Cited by 102
Adon, A. M., Zeng, X., Harrison, M. K., Sannem, S., Kiyokawa, H., Kaldis, P., & Saavedra, H. I. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00253-09 · Cited by 101
“redundancy in the regulation of DNA synthesis and specificity in their abilities to control development and tumorigenesis (2, 5, 6, 24, 25, 38, 52, 55, 61, 72, 77).”
BackgroundCyclin D1 Represses p300 Transactivation through a Cyclin-dependent Kinase-independent Mechanism
Fu, M., Wang, C., Rao, M., Wu, X., Bouras, T., Zhang, X., Li, Z., Jiao, X., Yang, J., Li, A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503188200 · Cited by 91
Aberrant Cyclin D1 splicing in cancer: from molecular mechanism to therapeutic modulation
Wang, J., Su, W., Zhang, T., Zhang, S., Lei, H., Ma, F., Shi, M., Shi, W., Xie, X., & Di, C. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05763-7 · Cited by 101
Zhang, Z., Du, G., Wang, C., Wen, X.-D., Calway, T., Li, Z., He, T., Du, W., Bissonnette, M., Musch, M. W., et al. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14022980 · Cited by 90
“A number of therapeutic agents have been observed to induce cyclin D1 degradation [35,36].”
BackgroundLanzino, M., Sisci, D., Morelli, C., Garofalo, C., Catalano, S., Casaburi, I., Capparelli, C., Giordano, C., Giordano, F., Maggiolini, M., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq278 · Cited by 90
“The biologically relevant role of cyclin D1 in breast tumourigenesis has been evidenced by several findings: mammary gland-targeted cyclin D1 over-expression resulted in mammary hyperplasia and adenocarcinoma in transgenic mice (9); cyclin D1 antisense blocked ErbB2-induced mammary tumour growth in vivo (10), and cycl…”
BackgroundWang, J., Wang, Q., Cui, Y., Liu, Z. Y., Zhao, W., Wang, C. L., Dong, Y., Hou, L., Hu, G., Luo, C., et al. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0692-4 · Cited by 106
Role of Cyclin D1 as a Mediator of c-Met– and β-Catenin–Induced Hepatocarcinogenesis
Patil, M. A., Lee, S. A., Macias, E., Lam, E. T., Xu, C., Jones, K. D., Ho, C., Rodriguez-Puebla, M., & Chen, X. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2514 · Cited by 90
“For example, CCND1 is necessary for oncogenic Ras- and HER2-induced but not Wnt-1– or Myc-induced breast cancer (22).”
BackgroundEYA1 Phosphatase Function Is Essential to Drive Breast Cancer Cell Proliferation through Cyclin D1
Wu, K., Li, Z., Cai, S., Tian, L., Chen, K., Wang, J., Hu, J., Sun, Y., Li, X., Ertel, A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4078 · Cited by 90
“These findings are consistent with evidence that cyclin D1 antisense reduces ErbB2-inducedmammary tumorigenesis in mice (12) and findings that breast tumor progression of MMTV-Ras or MMTV-ErbB2 transgenics is reduced in cyclin D1 / mice (25).”
The Rel/NF-κB/IκB Signal Transduction Pathway and Cancer
Gilmore, T. D. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-48158-8_10 · Cited by 91
Assar, E. A., Vidalle, M. C., Chopra, M., & Hafizi, S. (2016) · Tumor Biology · doi:10.1007/s13277-016-4798-3 · Cited by 90
“Furthermore, constitutive activation of NF-κB has been linked to tumor progression in hormone-independent breast cancer cell lines such as MDA-MB-231 [27], and breast gland development and breast carcinogenesis have been linked with NF-κBinduced cyclin D1 expression [28, 29] and selective activation of Bcl-3 and NF-κB…”
Wang, C., Li, Z., Fu, M., Bouras, T., & Pestell, R. G. (2004) · Cancer treatment and research · doi:10.1007/1-4020-7847-1_11 · Cited by 101
Cell-specific responses to loss of cyclin-dependent kinases
Berthet, C., & Kaldis, P. (2007) · Oncogene · doi:10.1038/sj.onc.1210243 · Cited by 97
“We mentioned that lack of cyclin D1 or Cdk4 confers resistance to breast or skin tumors (Robles et al., 1998; Yu et al., 2001, 2006; Rodriguez-Puebla et al., 2002; Reddy et al., 2005; Landis et al., 2006).”
BackgroundTkach, M., Rosemblit, C., Rivas, M. A., Proietti, C. J., Flaqué, M. C. D., Mercogliano, M. F., Béguelin, W., Maronna, E., Guzmán, P., Gercovich, F. G., et al. (2013) · Endocrine Related Cancer · doi:10.1530/erc-12-0194 · Cited by 99
“It is well acknowledged that cyclin D1 is a requirement for breast carcinogenesis (Yu et al. 2001).”
BackgroundAlao, J. P., Stavropoulou, A. V., Lam, E. W. ‐., Coombes, R. C., & Vigushin, D. M. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-8 · Cited by 103
“Thiazolidinediones and their derivatives have recently been shown to induce proteasome mediated proteolysis of cyclin D1 in MCF-7 cells [18].”
BackgroundRas redux: rethinking how and where Ras acts
Hingorani, S. R., & Tuveson, D. A. (2003) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(02)00017-5 · Cited by 103
Mechanisms of therapeutic CDK4/6 inhibition in breast cancer
Scott, S. C., Lee, S. S., & Abraham, J. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.01.006 · Cited by 96
Wang, Q., Guldner, I. H., Golomb, S. M., Sun, L., Harris, J. A., Lü, X., & Zhang, S. (2019) · Nature Communications · doi:10.1038/s41467-019-11729-1 · Cited by 106
Metadata
- Authors
- Yu, Q., Geng, Y., & Sicinski, P.
- Affiliations
- Harvard University (US)
- ORCID
- Yu, Qunyan
- Venue
- Nature
- Published
- 2001-06
- Volume
- 411
- Issue
- 6841
- Pages
- 1017-1021
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2098953839
- Cited by
- 934
- References
- 31
- Citations by year
- 2026: 9 · 2025: 5 · 2024: 12 · 2023: 26 · 2022: 19 · 2021: 24 · 2020: 32 · 2019: 22 · 2018: 24 · 2017: 36 · 2016: 25 · 2015: 33 · 2014: 32 · 2013: 33 · 2012: 35
- FWCI
- 33.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- cyclin D1, breast cancer, neu oncogene, oncogenic Ras, cell cycle, mammary epithelium, malignant transformation, c-Myc, Wnt1, targeted cancer therapy
- MeSH terms
- Animals, Antineoplastic Agents, Breast, Breast Neoplasms, Cell Transformation, Neoplastic, Crosses, Genetic, Female, Humans, Male, Mammary Tumor Virus, Mouse, Mammary Neoplasms, Experimental, Proto-Oncogene Proteins, Genes, ras, Tumor Cells, Cultured, Genes, myc, Genes, erbB-2, Cyclin D1, Genes, bcl-1, Genetic Predisposition to Disease, Zebrafish Proteins, Animals, Genetically Modified, Wnt Proteins, Wnt1 Protein, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.